The effect of glucocorticoids on serum cystatin C in identifying acute kidney injury: a propensity-matched cohort study

Table 3 Factors associated with sCysC using multivariate linear regression analysis

Independent variables	sCysC at ICU admission, mg/L
Independent variables	Standardized β	P
Baseline SCr, umol/L	0.002	< 0.001
SCr at ICU admission, umol/L	0.004	< 0.001
Grade of AKI	0.183	< 0.001
APACHE II score	0.009	< 0.001
Baseline eGFR, ml/min/1.73 m²	− 0.003	< 0.001
Admission type	−0.105	< 0.001
CKD, n (%)	0.227	< 0.001
Previous use of glucocorticoids, n (%)	0.092	0.003
Cumulative dose of prednisone, mg	0.0002	0.028
Serum albumin, g/L	−0.004	0.001
CHD, n (%)	0.118	0.001
Age	0.001	0.049
Constant	0.702 (Unstandardized)	< 0.001

APACHE II score Acute Physiology and Chronic Health Evaluation II score; AKI Acute kidney injury; BMI Body mass index; CKD Chronic kidney disease; CHD Coronary heart disease; CHF Chronic heart failure; COPD Chronic obstructive pulmonary disease; DM Diabetes mellitus; eGFR Estimated glomerular filtration rate; ICU Intensive care unit; KDIGO Kidney Disease: Improving Global Outcomes; n Sample size; SCr Serum creatinine; Mild-AKI: defined as reaching KDIGO stage 1 diagnostic criteria of AKI; Severe-AKI, defined as reaching KDIGO stage 2 or stage 3 diagnostic criteria of AKI
Independent variables included: baseline SCr, SCr at ICU admission, previous use of glucocorticoids, cumulative dose of prednisone, APACHE II score, grade of AKI, admission type, malignancy, stoke, hypertension, DM, CHD, CHF, COPD, chronic Liver disease, CKD, Albumin at admission, BMI, eGFR, sex, age. Variables not listed in the table were removed from the stepwise analysis. Adjusted R square 0.776

ISSN: 1471-2369